Longevity Protocols: Rapamycin, Metformin, and Related Medications This category involves prescription medications with established clinical use for their approved indications - applied in longevity contexts that are, to varying degrees, considered off-label
If budget is a factor and anti-inflammation is not a priority, Glow offers excellent value for money
In recent years, higher doses of some GLP-1 RAs have been used for obesity treatment, with liraglutide (3 mg) and semaglutide (2.4 mg) showing marked efficacy in inducing WL
Similar cardiovascular outcomes in patients with diabetes and established or high risk for cor- onary vascular disease treated with dulaglutide with and without baseline metformin
Studies show that more than half of patients who discontinue GLP-1 treatment regain at least some of the lost weight within a year, as hunger, cravings, and food noise return and drive them back to unhealthy habits